BMRA Biomerica, Inc.
USHealthcareAs of 2026-07-10 16:00
Why BMRA matters now
Biomerica, Inc. (BMRA) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.69 with +2.42% on the session and $5.2M in market capitalization; recent performance reads 1-month -24.79% and YTD -28.97%.
The latest financial table shown here is Q3 2026, with revenue of $987.0K, net income of $-1.3M, and EPS of $-0.44. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -57.3%.
The latest indexable market news headline is "Biomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Chin Eric filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.62
P/S
1.28
EV/EBITDA
-1.17
DCF Value
$-69.02
FCF Yield
-57.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
4.3%
Operating Margin
-123.7%
Net Margin
-96.5%
ROE
-98.1%
ROA
-85.6%
ROIC
-152.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $987.0K | $-1.3M | $-0.44 |
| Q2 2026 | $1.2M | $-1.3M | $-0.45 |
| Q1 2026 | $1.4M | $2.0K | $0.00 |
| Q4 2025 | $749.0K | $-1.5M | $-0.16 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
0.29
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.